HER2 positive breast cancer Treatment deescalation needs to be personalised

HER2 positive breast cancer: Treatment de-escalation needs to be personalised

De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr Carmen Criscitiello, European Institute of Oncology, Milan, Italy.  Her comments come on the occasion of the presentation of...

More From BioPortfolio on "HER2 positive breast cancer: Treatment de-escalation needs to be personalised"